Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices
April 01 2022 - 3:29AM
Business Wire
On the heels of the latest NICE guidelines,
Dexcom ONE is in review by NHS England for addition to the Drug
Tariff
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time
continuous glucose monitoring for people with diabetes, announced
today the new Dexcom ONE Continuous Glucose Monitoring System will
launch in the United Kingdom this May. The Dexcom ONE system is an
easy-to-use real-time CGM (rt-CGM) that will be more affordable and
accessible for people with diabetes in the UK. Dexcom ONE is
currently in review to be added to drug tariffs across the UK
regions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220401005092/en/
Dexcom ONE Product Family (Graphic:
Business Wire)
Karen Baxter, Vice President, UK & Ireland, Benelux,
France and Spain at Dexcom: “The diabetes community represents
a dynamic and inspiring group of individuals. It’s always been our
priority to provide them with innovative and impactful technology.
At Dexcom, we are constantly working to broaden access to CGM
technologies that drive improved health outcomes. The upcoming
launch of Dexcom ONE represents a significant step forward in
diabetes management and inclusion on the drug tariff would ensure
that more people benefit from this life changing technology. Should
Dexcom ONE be added to the NHS drug tariff, Dexcom will implement
an educational and support programme for people with diabetes and
healthcare professionals to ensure the diabetes community can
benefit as quickly as possible from reimbursement and wider
availability of Dexcom CGM.”
Dexcom ONE, a wearable sensor and transmitter, puts people
firmly in control of their diabetes. By continuously monitoring
glucose levels and sending real-time values wirelessly to a
compatible smart device* via the Dexcom ONE mobile app, the
technology eliminates the need for painful fingerpricks.† The app
was specially designed to be user friendly, displaying trend arrows
to show the speed and direction glucose levels are heading, making
in the moment treatment decisions easier. A range of customisable
alerts help users avoid potentially dangerous high or low glucose
events.
This news comes as the National Institute for Health and Care
Excellence (NICE) announced new guidance for adults and children
managing Type 1 diabetes. NICE now recommends that adults with Type
1 diabetes be offered a choice of glucose sensors, including
rt-CGM, based on their individual preferences, needs,
characteristics, and the functionality of the devices available.
Furthermore, the guidance also recommends that all children with
Type 1 diabetes be offered rt-CGM, together with education for both
them and their families and/or carers on how to use their device.
This not only improves access to potentially lifesaving technology
for people with diabetes, but also provides greater choice.
Dr. Emma Wilmot, Consultant Diabetologist, Derby Teaching
Hospitals NHS Foundation Trust; Honorary Associate (clinical)
Professor, University of Nottingham and Founder, Diabetes
Technology Network UK: “For many years, fingerstick blood
glucose testing has been a critical component of diabetes
self-management; however, self-monitoring can be time-consuming,
painful and difficult to fit into a busy day. We welcome the
addition of Dexcom ONE rt-CGM as an accessible option for people
with diabetes. This news marks an exciting milestone in diabetes
management and brings much needed sensor choice for people with
diabetes.”
Dexcom ONE will be part of a range of products offered by Dexcom
for people with diabetes in the UK that also includes the Dexcom G6
CGM system and the upcoming Dexcom G7 CGM system. Dexcom ONE shares
the same innovative sensing hardware as Dexcom G6 and is suitable
for people with Type 1 or Type 2 diabetes using insulin. The Dexcom
G6 CGM will continue to be available through existing channels to
people who require additional support to manage diabetes, for
example people who are hypo unaware, children and those using
connected devices.
Dexcom ONE will be available in the UK from May 2022.
About DexCom, Inc.
DexCom, Inc. empowers people to take control of diabetes through
innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, California, and with operations across
Europe, Dexcom has emerged as a leader of diabetes care technology.
By listening to the needs of users, caregivers, and providers,
Dexcom simplifies and improves diabetes management around the
world. For more information about Dexcom CGM, visit
www.dexcom.com.
*For a list of compatible devices, visit
www.dexcom.com/en-GB/compatibility
†If your glucose alerts and readings from Dexcom ONE do not
match symptoms or expectations, use a blood glucose meter to make
diabetes treatment decisions.
© 2022 Dexcom, Inc. Dexcom, Dexcom ONE, Dexcom G6 and Dexcom G7
are registered trademarks of DexCom, Inc. in the U.S., and may be
registered in other countries. All rights reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220401005092/en/
Stephanie Libous Allison+Partners for Dexcom
dexcomUK@allisonpr.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Jun 2024 to Jul 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Jul 2023 to Jul 2024